Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.28
- Piotroski Score 3.00
- Grade Neutral
- Symbol (OMER)
- Company Omeros Corporation
- Price $3.97
- Changes Percentage (1.15%)
- Change $0.05
- Day Low $3.84
- Day High $3.99
- Year High $5.68
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.91
- Trailing P/E Ratio -1.33
- Forward P/E Ratio -1.33
- P/E Growth -1.33
- Net Income $-117,813,000
Income Statement
Quarterly
Annual
Latest News of OMER
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Starbucks customers say wait times have gotten really long, so I went to check it out
Starbucks customers are facing long wait times due to understaffing and a surge in online orders. New CEO Brian Niccol aims to address these operational challenges. A comparison of ordering methods wa...
By Business Insider | 11 hours ago -
Brendan Donovan homers, hits RBI single as Cardinals beat Giants 6-1 in season finale
Brendan Donovan and Alec Burleson led the St. Louis Cardinals to a 6-1 victory over the San Francisco Giants. Rookie Michael McGreevy impressed with 8 innings pitched....
By AP NEWS | 23 hours ago -
Mariners overcome Shea Langeliers 9th inning homerun to beat A's 7-6 in 10 innings
The Seattle Mariners defeated the Oakland Athletics 7-6 in 10 innings, with Luke Raley's key plays and Leo Rivas' winning run. Cal Raleigh tied a record, and Eduard Bazardo got the win. Bryce Miller w...
By CBS News | 1 day ago
